Esperion Therapeutis.Inc. sell nvestor
Start price
18.03.23
/
50%
€1.46
Target price
18.03.24
€1.00
Performance (%)
-1.58%
End price
01.04.23
€1.43
Summary
This prediction ended on 01.04.23 with a price of €1.43. With a performance of -1.58%, the SELL prediction by nvestor was trending in the right direction. nvestor has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -7.041% | -7.041% | 103.136% | 52.014% |
| iShares Core DAX® | 0.789% | 1.975% | 13.390% | 49.835% |
| iShares Nasdaq 100 | 4.226% | 4.344% | 39.717% | 89.762% |
| iShares Nikkei 225® | 3.285% | 6.991% | 49.894% | 64.380% |
| iShares S&P 500 | 2.496% | 2.759% | 30.229% | 64.245% |
Comments by nvestor for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.